Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Internists And Other Physician Groups Support Comparative Effectiveness Provisions In Proposed Legislation
The American College of Physicians (ACP) joined with two other physician groups to offer strong support for the Comparative Effectiveness Research (CER) provisions included in the Tri-Committee health reform bill about to be considered in the House. The Tri-Committee, which unveiled its proposed legislation on June 19, is made up of the House Ways and Means, Energy and Commerce, and Education and Labor Committees.

Having A Higher Purpose In Life Reduces Risk Of Death Among Older Adults
Possessing a greater purpose in life is associated with lower mortality rates among older adults according to a new study by researchers at Rush University Medical Center.
News of the day
2009/044 NICE Guidance Recommends Tenofovir Disoproxil For Hepatitis B
The National Institute for Health and Clinical Excellence (NICE) has today (22 July) published final guidance recommending the use of tenofovir disoproxil for the treatment of people with chronic HBeAg-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated.
Oncology

Meridian Bioscience Receives FDA Clearance For New Rapid Campylobacter Test

Meridian Bioscience, Inc. (NASDAQ: VIVO) announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for a new rapid test for Campylobacter, ImmunoCard STAT!® CAMPY. This new test provides fast and accurate detection of Campylobacter bacteria, one of the most common causes of diarrheal illness and the most common bacterial cause of foodborne illness in the United States. Approximately 20 million stool culture tests are conducted each year in the U.S. to detect the illness, known as Campylobacteriosis. Campylobacter is most often transmitted by poorly cooked poultry or person-to-person contact. There is a real need for the ImmunoCard STAT!® CAMPY because of its simplified, easy to perform procedure that provides patient results in 20 minutes. In addition, ImmunoCard STAT!® CAMPY provides a solution to several concerns associated with culture testing, currently the most commonly practiced lab technique for detecting the Campylobacter bacteria. With culture, there is a potential for reduction in sensitivity due to variable culturing procedures, specimen viability, and inhibitory antibiotics in culture media. ImmunoCard STAT!® CAMPY dramatically reduces these concerns with a consistent method that measures the bacterial antigen instead of measuring the viability of this fragile bacteria in an environment that is less inhibitory than current culturing procedures. John A. Kraeutler, Chief Executive Officer, stated, "ImmunoCard STAT!® CAMPY is a significant addition to our foodborne category because it provides laboratories with a rapid, accurate and easy to perform platform for the detection of Campylobacter. This innovative assay, along with Meridian"s Premier™ CAMPY and toxigenic E. coli tests, demonstrates Meridian"s emerging leadership in foodborne testing. ImmunoCard STAT!® CAMPY is already in distribution by Meridian Bioscience Europe for the Company"s European markets and was also recently approved for sale in Canada." Meridian Bioscience, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009